27994747|t|Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes
27994747|a|GPR142 has been identified as a potential glucose-stimulated insulin secretion (GSIS) target for the treatment of type 2 diabetes mellitus (T2DM). A class of triazole GPR142 agonists was discovered through a high throughput screen. The lead compound 4 suffered from poor metabolic stability and poor solubility. Lead optimization strategies to improve potency, efficacy, metabolic stability, and solubility are described. This optimization led to compound 20e, which showed significant reduction of glucose excursion in wild-type but not in GPR142 deficient mice in an oral glucose tolerance test (oGTT) study. These studies provide strong evidence that reduction of glucose excursion through treatment with 20e is GPR142 -mediated, and GPR142 agonists could be used as a potential treatment for type 2 diabetes.
27994747	38	53	Triazole Series	T103	UMLS:C1689939
27994747	57	63	GPR142	T103	UMLS:C1570380
27994747	64	72	Agonists	T103	UMLS:C0243192
27994747	94	109	Type 2 Diabetes	T038	UMLS:C0011860
27994747	110	116	GPR142	T103	UMLS:C1570380
27994747	152	188	glucose-stimulated insulin secretion	T038	UMLS:C2245393
27994747	190	194	GSIS	T038	UMLS:C2245393
27994747	224	248	type 2 diabetes mellitus	T038	UMLS:C0011860
27994747	250	254	T2DM	T038	UMLS:C0011860
27994747	259	276	class of triazole	T103	UMLS:C1689939
27994747	277	283	GPR142	T103	UMLS:C1570380
27994747	284	292	agonists	T103	UMLS:C0243192
27994747	318	340	high throughput screen	T058	UMLS:C0872187
27994747	346	361	lead compound 4	T103	UMLS:C1254351
27994747	454	461	improve	T033	UMLS:C0184511
27994747	557	569	compound 20e	T103	UMLS:C1254351
27994747	609	626	glucose excursion	T033	UMLS:C0428548
27994747	630	639	wild-type	T204	UMLS:C1520150
27994747	651	657	GPR142	T103	UMLS:C1723023
27994747	668	672	mice	T204	UMLS:C0025929
27994747	679	706	oral glucose tolerance test	T058	UMLS:C0029161
27994747	708	712	oGTT	T058	UMLS:C0029161
27994747	727	734	studies	T062	UMLS:C2603343
27994747	777	794	glucose excursion	T033	UMLS:C0428548
27994747	818	821	20e	T103	UMLS:C1254351
27994747	825	831	GPR142	T103	UMLS:C1723023
27994747	847	853	GPR142	T103	UMLS:C1723023
27994747	854	862	agonists	T103	UMLS:C0243192
27994747	906	921	type 2 diabetes	T038	UMLS:C0011860